ReviewFrontiers in bioengineering and biotechnology2025
Nanoarchitecting intelligently encapsulated designs for improved cancer therapy.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Combinatorial cancer therapy mediated by hydroxyapatite nanoparticles: a comprehensive review.Medical oncology (Northwood, London, England) · 2026Review
- In situ sol-gel-sol transformation formed by sodium alginate realizes folic acid-modified chitosan nanoparticles to deliver hops β-acids for colorectal cancer therapy.Journal of nanobiotechnology · 2026Article
- Hydrogen peroxide self-supplied nanozyme system for synergistic prostate cancer therapy via ferroptosis/pyroptosis and CaJournal of nanobiotechnology · 2026Article
- Nanoencapsulation of Tomentosin-RichPharmaceutics · 2026Article
- Cell encapsulated biomaterials for translational medicine.Bioactive materials · 2026Review
- Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies.Frontiers in oncology · 2026Review
- CD44 targeted functionalized nanocarriers for non-small cell lung cancer.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the success in exploring various aspects of origination and therapeutic strategies, cancer has remained one of the most dreadful metabolic disorders due to failure to eradicate tumors comprehensively and frequent recurrence because of acquired resistance to the drugs. Recently, several advancements have been evidenced in the fabrication of various smart nanocarriers encapsulated with multiple components. Several reasons for smart nanoencapsulation include the enhancement of the bioavailability of drugs, precise targetability to reduce adverse effects on normal cells, and the ability to enable controlled drug release rates at the tumor sites. In addition, these smart nanocarriers protect encapsulated therapeutic cargo from deactivation, responsively delivering it based on the physiological or pathological characteristics of tumors. In this review, we present various smart approaches for cancer therapy, including organic materials, inorganic components, and their composites, as well as biomembrane-based nanoencapsulation strategies. These nanoencapsulation strategies, along with practical applications and their potential in cancer treatment, are discussed in depth, highlighting advantages and disadvantages, as well as aiming to reveal the ultimate prospects of nanoencapsulation in enhancing drug delivery efficiency and targeted cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.